JP2011517932A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011517932A5 JP2011517932A5 JP2010548901A JP2010548901A JP2011517932A5 JP 2011517932 A5 JP2011517932 A5 JP 2011517932A5 JP 2010548901 A JP2010548901 A JP 2010548901A JP 2010548901 A JP2010548901 A JP 2010548901A JP 2011517932 A5 JP2011517932 A5 JP 2011517932A5
- Authority
- JP
- Japan
- Prior art keywords
- mir
- biomarker
- cluster
- cells
- cll
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000004027 cell Anatomy 0.000 claims 37
- 239000000090 biomarker Substances 0.000 claims 36
- 238000000034 method Methods 0.000 claims 28
- 108091070501 miRNA Proteins 0.000 claims 24
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 21
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims 18
- 239000008194 pharmaceutical composition Substances 0.000 claims 18
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 17
- 206010028980 Neoplasm Diseases 0.000 claims 15
- 201000011510 cancer Diseases 0.000 claims 14
- 208000032839 leukemia Diseases 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 10
- 230000000692 anti-sense effect Effects 0.000 claims 9
- 239000000203 mixture Substances 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 8
- 108091074057 miR-16-1 stem-loop Proteins 0.000 claims 8
- 239000000523 sample Substances 0.000 claims 7
- 239000003795 chemical substances by application Substances 0.000 claims 6
- 102000004169 proteins and genes Human genes 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 6
- 102000006818 Cell Adhesion Molecule-1 Human genes 0.000 claims 5
- 108010072135 Cell Adhesion Molecule-1 Proteins 0.000 claims 5
- 239000012472 biological sample Substances 0.000 claims 5
- 239000003153 chemical reaction reagent Substances 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 230000002401 inhibitory effect Effects 0.000 claims 4
- 239000003550 marker Substances 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 230000004075 alteration Effects 0.000 claims 3
- 239000000063 antileukemic agent Substances 0.000 claims 3
- 238000010837 poor prognosis Methods 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 241001465754 Metazoa Species 0.000 claims 2
- 239000013068 control sample Substances 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 238000011275 oncology therapy Methods 0.000 claims 2
- 238000004393 prognosis Methods 0.000 claims 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims 1
- 101150017888 Bcl2 gene Proteins 0.000 claims 1
- 241000282412 Homo Species 0.000 claims 1
- 101000611943 Homo sapiens Programmed cell death protein 4 Proteins 0.000 claims 1
- 101001130308 Homo sapiens Ras-related protein Rab-21 Proteins 0.000 claims 1
- 101000633708 Homo sapiens Src kinase-associated phosphoprotein 2 Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 102100040992 Programmed cell death protein 4 Human genes 0.000 claims 1
- 102000020146 Rab21 Human genes 0.000 claims 1
- 102100029213 Src kinase-associated phosphoprotein 2 Human genes 0.000 claims 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 claims 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 claims 1
- 230000000719 anti-leukaemic effect Effects 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 230000001632 homeopathic effect Effects 0.000 claims 1
- 210000000265 leukocyte Anatomy 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 239000000047 product Substances 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 238000001890 transfection Methods 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6740608P | 2008-02-28 | 2008-02-28 | |
| US61/067,406 | 2008-02-28 | ||
| PCT/US2009/035463 WO2009108856A2 (en) | 2008-02-28 | 2009-02-27 | Microrna signatures associated with human chronic lymphocytic leukemia (ccl) and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011517932A JP2011517932A (ja) | 2011-06-23 |
| JP2011517932A5 true JP2011517932A5 (https=) | 2013-03-07 |
Family
ID=41016725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010548901A Pending JP2011517932A (ja) | 2008-02-28 | 2009-02-27 | ヒト慢性リンパ球性白血病（ｃｃｌ）と関連するマイクロｒｎａシグネチャーおよびその使用 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20110052502A1 (https=) |
| EP (1) | EP2254668A4 (https=) |
| JP (1) | JP2011517932A (https=) |
| CN (1) | CN102015027A (https=) |
| AU (1) | AU2009219193A1 (https=) |
| CA (1) | CA2717026A1 (https=) |
| WO (1) | WO2009108856A2 (https=) |
Families Citing this family (85)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2295604B1 (en) * | 2004-02-09 | 2015-04-08 | Thomas Jefferson University | Diagnosis and treatment of cancers with microRNA located in or near cancer-associated chromosomal features |
| CA2857881A1 (en) | 2004-11-12 | 2006-12-28 | Asuragen, Inc. | Methods and compositions involving mirna and mirna inhibitor molecules |
| JP5489459B2 (ja) | 2005-08-01 | 2014-05-14 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | 乳癌の診断、予後及び治療のためのマイクロｒｎａに基づいた方法及び組成物 |
| CA2845251A1 (en) | 2005-09-12 | 2007-03-22 | The Ohio State University Research Foundation | Compositions for the therapy of bcl2-associated cancers and methods of preparation thereof |
| EP2487258B1 (en) | 2006-01-05 | 2014-10-01 | The Ohio State University Research Foundation | MicroRNA-based methods for the diagnosis of colon, pancreas and stomach cancer |
| JP5490413B2 (ja) | 2006-01-05 | 2014-05-14 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | 膵内分泌腫瘍及び膵腺房腫瘍におけるマイクロｒｎａ発現異常 |
| CN102943108B (zh) | 2006-01-05 | 2014-05-21 | 俄亥俄州立大学研究基金会 | 用于肺癌的诊断、预后和治疗的基于微小rna的方法和组合物 |
| ES2446362T3 (es) | 2006-03-20 | 2014-03-07 | The Ohio State University Research Foundation | Huellas de microARN durante megacariocipoyesis humana |
| CA2657030A1 (en) | 2006-07-13 | 2008-01-17 | The Ohio State University Research Foundation, An Instrumentality Of The State Of Ohio | Micro-rna-based methods and compositions for the diagnosis and treatment of colon cancer-related diseases |
| CN101535505A (zh) | 2006-09-19 | 2009-09-16 | 俄亥俄州立大学研究基金会 | 慢性淋巴细胞性白血病(CLL)中受miR-29和miR-181调控的TCL1的表达 |
| EP2087135B8 (en) | 2006-11-01 | 2013-07-24 | The Ohio State University Research Foundation | Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma |
| CN105256004A (zh) | 2007-01-31 | 2016-01-20 | 俄亥俄州立大学研究基金会 | 用于急性髓细胞白血病(aml)的诊断、预后和治疗的基于微rna的方法和组合物 |
| ES2527648T3 (es) | 2007-06-08 | 2015-01-28 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Métodos para determinar el subtipo de carcinoma hepatocelular |
| EP2719773A3 (en) | 2007-06-15 | 2014-07-30 | The Ohio State University Research Foundation | miRNA as marker for acute lamphomic leucemia |
| ES2496172T3 (es) | 2007-07-31 | 2014-09-18 | The Ohio State University Research Foundation | Métodos para invertir la metilación por selección dirigida de DNMT3A y DNMT3B |
| JP2010535473A (ja) | 2007-08-03 | 2010-11-25 | ズィ、オハイオウ、ステイト、ユーニヴァーサティ、リサーチ、ファウンデイシャン | ｎｃＲＮＡをコードする超保存領域 |
| CA2696887C (en) | 2007-08-22 | 2016-06-28 | The Ohio State University Research Foundation | Methods and compositions for inducing deregulation of epha7 and erk phosphorylation in human acute leukemias |
| CN102137927B (zh) | 2007-10-26 | 2014-03-12 | 俄亥俄州立大学研究基金会 | 鉴定脆性组氨酸三联体(Fhit)相互作用的方法及其用途 |
| ES2433940T3 (es) | 2008-06-11 | 2013-12-13 | The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Uso de la familia miR-26 como marcador predictivo del carcinoma hepatocelular y sensibilidad a la terapia |
| US20130139273A1 (en) * | 2010-06-24 | 2013-05-30 | The Ohio State University | Chronic Lymphocytic Leukemia Modeled in Mouse by Targeted miR-29 Expression |
| US8933051B2 (en) | 2010-09-30 | 2015-01-13 | University Of Zurich | Treatment of B-cell lymphoma with microRNA |
| JP5931897B2 (ja) | 2010-11-12 | 2016-06-08 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイションＴｈｅ Ｏｈｉｏ Ｓｔａｔｅ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ｆｏｕｎｄａｔｉｏｎ | マイクロｒｎａ−２１、ミスマッチ修復および結腸直腸癌に関連する物質および方法 |
| CA2817982C (en) | 2010-11-15 | 2020-06-30 | The Regents Of The University Of Michigan | Controlled release mucoadhesive systems |
| WO2012122239A1 (en) | 2011-03-07 | 2012-09-13 | The Ohio State University | MUTATOR ACTIVITY INDUCED BY MICRORNA-155 (miR-155) LINKS INFLAMMATION AND CANCER |
| AU2012323924A1 (en) | 2011-10-14 | 2014-05-29 | The Ohio State University | Methods and materials related to ovarian cancer |
| CA2859430A1 (en) | 2011-12-13 | 2013-06-20 | Ohio State Innovation Foundation | Methods and compositions related to mir-21 and mir-29a, exosome inhibition, and cancer metastasis |
| CN102559876A (zh) * | 2011-12-19 | 2012-07-11 | 苏州福英基因科技有限公司 | 癌症病理演变前期microrna-16-1水平原位杂交检测试剂盒及检测方法和应用 |
| US8859202B2 (en) | 2012-01-20 | 2014-10-14 | The Ohio State University | Breast cancer biomarker signatures for invasiveness and prognosis |
| JP6156621B2 (ja) * | 2012-02-14 | 2017-07-05 | 国立大学法人 岡山大学 | Ａｔｌｌの診断のためのデータ取得方法、ａｔｌｌ診断用キットおよびａｔｌｌ診断システム |
| KR101472089B1 (ko) | 2012-05-24 | 2014-12-16 | 광주과학기술원 | ＩＧＳＦ４ 억제제를 유효성분으로 포함하는 Ｔｈ１―매개 면역 질환 또는 Ｔｈ２―매개 면역 질환 예방 또는 치료용 약제학적 조성물 |
| WO2014093924A1 (en) | 2012-12-13 | 2014-06-19 | Moderna Therapeutics, Inc. | Modified nucleic acid molecules and uses thereof |
| WO2014081507A1 (en) | 2012-11-26 | 2014-05-30 | Moderna Therapeutics, Inc. | Terminally modified rna |
| US20140200261A1 (en) | 2013-01-17 | 2014-07-17 | Moderna Therapeutics, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
| EP2976110A4 (en) | 2013-03-20 | 2016-11-23 | Padma Arunachalam | KITS AND METHODS FOR THE ASSESSMENT, SELECTION AND CHARACTERIZATION OF TISSUE CULTURAL MODELS USING MICRO-RNA PROFILES |
| WO2014168922A2 (en) * | 2013-04-08 | 2014-10-16 | The Regents Of The University Of California | G-protein coupled receptor-associated diagnostics and therapeutics for b-cell chronic lymphocytic leukemia |
| EP3461904A1 (en) | 2014-11-10 | 2019-04-03 | ModernaTX, Inc. | Alternative nucleic acid molecules containing reduced uracil content and uses thereof |
| EP3405579A1 (en) | 2016-01-22 | 2018-11-28 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
| EP3443001B1 (en) | 2016-04-11 | 2025-04-30 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
| US11497740B2 (en) | 2016-04-29 | 2022-11-15 | The Board Of Regents Of The University Of Texas System | Use of Jumonji C demethylase inhibitors for the treatment and prevention of chemotherapy resistance and radioresistance in cancer |
| KR102469450B1 (ko) | 2016-05-18 | 2022-11-22 | 모더나티엑스, 인크. | 인터류킨-12 (il12)를 코딩하는 폴리뉴클레오티드 및 그의 용도 |
| WO2017218704A1 (en) | 2016-06-14 | 2017-12-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| US11427838B2 (en) | 2016-06-29 | 2022-08-30 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders |
| WO2018002762A1 (en) | 2016-06-29 | 2018-01-04 | Crispr Therapeutics Ag | Materials and methods for treatment of amyotrophic lateral sclerosis (als) and other related disorders |
| EP3478828B1 (en) | 2016-06-29 | 2024-09-04 | CRISPR Therapeutics AG | Materials and methods for treatment of friedreich ataxia and other related disorders |
| AU2017292173B2 (en) | 2016-07-06 | 2022-01-13 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of pain related disorders |
| JP7305534B2 (ja) | 2016-07-06 | 2023-07-10 | バーテックス ファーマシューティカルズ インコーポレイテッド | 疼痛関連障害を処置するための物質及び方法 |
| SG11201903674YA (en) | 2016-10-26 | 2019-05-30 | Modernatx Inc | Messenger ribonucleic acids for enhancing immune responses and methods of use thereof |
| US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| JP2020514321A (ja) | 2017-02-01 | 2020-05-21 | モデルナティーエックス， インコーポレイテッド | 活性化がん遺伝子変異ペプチドをコードする免疫調節治療ｍＲＮＡ組成物 |
| JP2020508056A (ja) | 2017-02-22 | 2020-03-19 | クリスパー・セラピューティクス・アクチェンゲゼルシャフトＣＲＩＳＰＲ Ｔｈｅｒａｐｅｕｔｉｃｓ ＡＧ | 遺伝子編集のための組成物および方法 |
| US20200040061A1 (en) | 2017-02-22 | 2020-02-06 | Crispr Therapeutics Ag | Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders |
| WO2018154462A2 (en) | 2017-02-22 | 2018-08-30 | Crispr Therapeutics Ag | Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders |
| EP3585899A1 (en) | 2017-02-22 | 2020-01-01 | CRISPR Therapeutics AG | Materials and methods for treatment of primary hyperoxaluria type 1 (ph1) and other alanine-glyoxylate aminotransferase (agxt) gene related conditions or disorders |
| US11559588B2 (en) | 2017-02-22 | 2023-01-24 | Crispr Therapeutics Ag | Materials and methods for treatment of Spinocerebellar Ataxia Type 1 (SCA1) and other Spinocerebellar Ataxia Type 1 Protein (ATXN1) gene related conditions or disorders |
| US20200131498A1 (en) | 2017-06-14 | 2020-04-30 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase |
| WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
| MA50877A (fr) | 2017-11-21 | 2020-09-30 | Bayer Healthcare Llc | Matériaux et méthodes pour le traitement de la rétinite pigmentaire autosomique dominante |
| WO2019123430A1 (en) | 2017-12-21 | 2019-06-27 | Casebia Therapeutics Llp | Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp) |
| WO2019123429A1 (en) | 2017-12-21 | 2019-06-27 | Casebia Therapeutics Llp | Materials and methods for treatment of usher syndrome type 2a |
| JP2021512090A (ja) | 2018-01-30 | 2021-05-13 | モデルナティーエックス， インコーポレイテッド | 免疫細胞に薬剤を送達するための組成物及び方法 |
| CN108434169A (zh) * | 2018-02-01 | 2018-08-24 | 滨州医学院 | 一种Mir-218-2在胶质细胞瘤中的应用 |
| US10941403B2 (en) | 2018-04-02 | 2021-03-09 | Oregon Health & Science University | Microrna inhibitors as anti-cancer therapeutics |
| EP3773745A1 (en) | 2018-04-11 | 2021-02-17 | ModernaTX, Inc. | Messenger rna comprising functional rna elements |
| WO2019241315A1 (en) | 2018-06-12 | 2019-12-19 | Obsidian Therapeutics, Inc. | Pde5 derived regulatory constructs and methods of use in immunotherapy |
| CN113271926A (zh) | 2018-09-20 | 2021-08-17 | 摩登纳特斯有限公司 | 脂质纳米颗粒的制备及其施用方法 |
| WO2020086742A1 (en) | 2018-10-24 | 2020-04-30 | Obsidian Therapeutics, Inc. | Er tunable protein regulation |
| JP7635131B2 (ja) | 2019-01-31 | 2025-02-25 | モデルナティエックス インコーポレイテッド | 脂質ナノ粒子の調製方法 |
| KR20210149251A (ko) | 2019-03-08 | 2021-12-08 | 옵시디안 테라퓨틱스, 인크. | 조율가능한 조절을 위한 인간 탄산 무수화효소 2 조성물 및 방법 |
| EP3987027A1 (en) | 2019-06-24 | 2022-04-27 | ModernaTX, Inc. | Endonuclease-resistant messenger rna and uses thereof |
| WO2020263985A1 (en) | 2019-06-24 | 2020-12-30 | Modernatx, Inc. | Messenger rna comprising functional rna elements and uses thereof |
| WO2021046451A1 (en) | 2019-09-06 | 2021-03-11 | Obsidian Therapeutics, Inc. | Compositions and methods for dhfr tunable protein regulation |
| US20230285297A1 (en) | 2020-01-31 | 2023-09-14 | Modernatx, Inc. | Methods of preparing lipid nanoparticles |
| JP2023535225A (ja) | 2020-07-24 | 2023-08-16 | ストランド セラピューティクス インコーポレイテッド | 改変ヌクレオチドを含む脂質ナノ粒子 |
| KR20230167008A (ko) | 2020-08-06 | 2023-12-07 | 모더나티엑스, 인크. | 지질 나노입자의 제조 방법 |
| US20240166707A1 (en) | 2021-01-08 | 2024-05-23 | Strand Therapeutics Inc. | Expression constructs and uses thereof |
| CA3171589A1 (en) | 2021-05-03 | 2022-11-03 | Moritz THRAN | Improved nucleic acid sequence for cell type specific expression |
| WO2023166425A1 (en) | 2022-03-01 | 2023-09-07 | Crispr Therapeutics Ag | Methods and compositions for treating angiopoietin-like 3 (angptl3) related conditions |
| EP4514328A1 (en) | 2022-04-26 | 2025-03-05 | Strand Therapeutics Inc. | Lipid nanoparticles comprising venezuelan equine encephalitis (vee) replicon and uses thereof |
| EP4561547A1 (en) | 2022-07-29 | 2025-06-04 | ModernaTX, Inc. | Lipid nanoparticle compositions comprising phospholipid derivatives and related uses |
| WO2024026475A1 (en) | 2022-07-29 | 2024-02-01 | Modernatx, Inc. | Compositions for delivery to hematopoietic stem and progenitor cells (hspcs) and related uses |
| WO2024026482A1 (en) | 2022-07-29 | 2024-02-01 | Modernatx, Inc. | Lipid nanoparticle compositions comprising surface lipid derivatives and related uses |
| EP4703374A1 (en) | 2023-04-28 | 2026-03-04 | Shenzhen Shenxin Biotechnology Co., Ltd. | Modified delivery vector and use thereof |
| EP4727914A1 (en) | 2023-06-14 | 2026-04-22 | ModernaTX, Inc. | Compounds and compositions for delivery of therapeutic agents |
| WO2025160381A1 (en) | 2024-01-26 | 2025-07-31 | Modernatx, Inc. | Methods of preparing lipid nanoparticles |
| WO2025166202A1 (en) | 2024-01-31 | 2025-08-07 | Modernatx, Inc. | Lipid nanoparticle compositions comprising sialic acid derivatives and the uses thereof |
Family Cites Families (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2010A (en) * | 1841-03-18 | Machine foe | ||
| US2007A (en) * | 1841-03-16 | Improvement in the mode of harvesting grain | ||
| US4196265A (en) * | 1977-06-15 | 1980-04-01 | The Wistar Institute | Method of producing antibodies |
| US4608337A (en) * | 1980-11-07 | 1986-08-26 | The Wistar Institute | Human hybridomas and the production of human monoclonal antibodies by human hybridomas |
| US5015568A (en) * | 1986-07-09 | 1991-05-14 | The Wistar Institute | Diagnostic methods for detecting lymphomas in humans |
| US5202429A (en) * | 1986-07-09 | 1993-04-13 | The Wistar Institute | DNA molecules having human BCL-2 gene sequences |
| US5198338A (en) * | 1989-05-31 | 1993-03-30 | Temple University | Molecular probing for human t-cell leukemia and lymphoma |
| US6040140A (en) * | 1991-12-11 | 2000-03-21 | Thomas Jefferson University | Methods for screening and treating leukemias resulting from all-1 region chromosome abnormalities |
| US5633135A (en) * | 1991-12-11 | 1997-05-27 | Thomas Jefferson University | Chimeric nucleic acids and proteins resulting from ALL-1 region chromosome abnormalities |
| WO1993012136A1 (en) * | 1991-12-11 | 1993-06-24 | Thomas Jefferson University | Detection and treatment of acute leukemias resulting from chromosome abnormalities in the all-1 region |
| US5674682A (en) * | 1992-10-29 | 1997-10-07 | Thomas Jefferson University | Nucleic acid primers for detecting micrometastasis of prostate cancer |
| WO1994010343A1 (en) * | 1992-10-29 | 1994-05-11 | Thomas Jefferson University | Methods of detecting micrometastasis of prostate cancer |
| US5985598A (en) * | 1994-10-27 | 1999-11-16 | Thomas Jefferson University | TCL-1 gene and protein and related methods and compositions |
| US7175995B1 (en) * | 1994-10-27 | 2007-02-13 | Thomas Jefferson University | TCL-1 protein and related methods |
| US5928884A (en) * | 1996-02-09 | 1999-07-27 | Croce; Carlo M. | FHIT proteins and nucleic acids and methods based thereon |
| US6242212B1 (en) * | 1996-02-09 | 2001-06-05 | Thomas Jefferson University | Fragile histidine triad (FHIT) nucleic acids and methods of producing FHIT proteins |
| AU6951098A (en) * | 1997-04-04 | 1998-10-30 | The Texas A & M University System | Noninvasive detection of colonic biomarkers using fecal messenger rna |
| WO2000003685A2 (en) * | 1998-07-20 | 2000-01-27 | Thomas Jefferson University | Nitrilase homologs |
| AU5128999A (en) * | 1998-07-24 | 2000-02-14 | Yeda Research And Development Co. Ltd. | Prevention of metastasis with 5-aza-2'-deoxycytidine |
| US7141417B1 (en) * | 1999-02-25 | 2006-11-28 | Thomas Jefferson University | Compositions, kits, and methods relating to the human FEZ1 gene, a novel tumor suppressor gene |
| EP1276879A4 (en) * | 2000-04-11 | 2004-12-22 | Univ Jefferson | MUIR-TORRE-LIKE SYNDROME IN Fhit-DEFECTIVE MICE |
| US20020086331A1 (en) * | 2000-05-16 | 2002-07-04 | Carlo Croce | Crystal structure of worm NitFhit reveals that a Nit tetramer binds two Fhit dimers |
| US7060811B2 (en) * | 2000-10-13 | 2006-06-13 | Board Of Regents, The University Of Texas System | WWOX: a tumor suppressor gene mutated in multiple cancers |
| US20040033502A1 (en) * | 2001-03-28 | 2004-02-19 | Amanda Williams | Gene expression profiles in esophageal tissue |
| EP2390331B1 (en) * | 2001-09-28 | 2018-04-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | MicroRNA molecules |
| US7371736B2 (en) * | 2001-11-07 | 2008-05-13 | The Board Of Trustees Of The University Of Arkansas | Gene expression profiling based identification of DKK1 as a potential therapeutic targets for controlling bone loss |
| GB0128898D0 (en) * | 2001-12-03 | 2002-01-23 | Biotech Res Ventures Pte Ltd | Materials and methods relating to the stabilization and activation of a tumour suppressor protein |
| JP2005522677A (ja) * | 2002-04-08 | 2005-07-28 | シファーゲン バイオシステムズ， インコーポレイテッド | 肝細胞癌の血清バイオマーカー |
| DE60329836D1 (de) * | 2002-04-29 | 2009-12-10 | Univ Jefferson | Humane chronische lymphozytische leukämie im mausmodell durch gezielte expression von tcl1 |
| AU2003273542A1 (en) * | 2002-05-31 | 2003-12-19 | The Board Of Trustees Of The Leland Stanford Junior University | Methods of identifying and isolating stem cells and cancer stem cells |
| CA2501602A1 (en) * | 2002-10-11 | 2004-04-22 | Thomas Jefferson University | Novel tumor suppressor gene and compositions and methods for making and using the same |
| EP1567007B1 (en) * | 2002-11-13 | 2012-02-22 | Thomas Jefferson University | Compositions and methods for cancer diagnosis and therapy |
| US20050069918A1 (en) * | 2003-05-29 | 2005-03-31 | Francois Claret | JAB1 as a prognostic marker and a therapeutic target for human cancer |
| US7683036B2 (en) * | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
| US8106180B2 (en) * | 2003-08-07 | 2012-01-31 | Whitehead Institute For Biomedical Research | Methods and products for expression of micro RNAs |
| US20050037362A1 (en) * | 2003-08-11 | 2005-02-17 | Eppendorf Array Technologies, S.A. | Detection and quantification of siRNA on microarrays |
| CN1890382A (zh) * | 2003-09-24 | 2007-01-03 | 肿瘤疗法科学股份有限公司 | 检测、诊断和治疗肝细胞癌(hcc)的方法 |
| EP2295604B1 (en) * | 2004-02-09 | 2015-04-08 | Thomas Jefferson University | Diagnosis and treatment of cancers with microRNA located in or near cancer-associated chromosomal features |
| CA2566519C (en) * | 2004-05-14 | 2020-04-21 | Rosetta Genomics Ltd. | Micrornas and uses thereof |
| EP2290071B1 (en) * | 2004-05-28 | 2014-12-31 | Asuragen, Inc. | Methods and compositions involving microRNA |
| US7635563B2 (en) * | 2004-06-30 | 2009-12-22 | Massachusetts Institute Of Technology | High throughput methods relating to microRNA expression analysis |
| EP1791567B1 (en) * | 2004-08-10 | 2015-07-29 | Alnylam Pharmaceuticals Inc. | Chemically modified oligonucleotides |
| US20060037088A1 (en) * | 2004-08-13 | 2006-02-16 | Shulin Li | Gene expression levels as predictors of chemoradiation response of cancer |
| US7642348B2 (en) * | 2004-10-04 | 2010-01-05 | Rosetta Genomics Ltd | Prostate cancer-related nucleic acids |
| FR2877350B1 (fr) * | 2004-11-03 | 2010-08-27 | Centre Nat Rech Scient | IDENTIFICATION ET UTILISATION DE miRNAs IMPLIQUES DANS LA DIFFERENCIATION DE CELLULES ISSUES D'UNE LEUCEMIE MYELOIDE |
| CA2857881A1 (en) * | 2004-11-12 | 2006-12-28 | Asuragen, Inc. | Methods and compositions involving mirna and mirna inhibitor molecules |
| WO2006066158A2 (en) * | 2004-12-14 | 2006-06-22 | Alnylam Pharmaceuticals, Inc. | Rnai modulation of mll-af4 and uses thereof |
| WO2006069584A2 (en) * | 2004-12-29 | 2006-07-06 | Exiqon A/S | NOVEL OLIGONUCLEOTIDE COMPOSITIONS AND PROBE SEQUENCES USEFUL FOR DETECTION AND ANALYSIS OF microRNAs AND THEIR TARGET mRNAs |
| US20090123912A1 (en) * | 2005-01-25 | 2009-05-14 | Rosetta Inpharmatics Llc | Methods for quantitating small RNA molecules |
| US20070065840A1 (en) * | 2005-03-23 | 2007-03-22 | Irena Naguibneva | Novel oligonucleotide compositions and probe sequences useful for detection and analysis of microRNAS and their target mRNAS |
| US20070065844A1 (en) * | 2005-06-08 | 2007-03-22 | Massachusetts Institute Of Technology | Solution-based methods for RNA expression profiling |
| US20070213292A1 (en) * | 2005-08-10 | 2007-09-13 | The Rockefeller University | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
| WO2007021896A2 (en) * | 2005-08-10 | 2007-02-22 | Alnylam Pharmaceuticals, Inc. | Chemically modified oligonucleotides for use in modulating micro rna and uses thereof |
| CA2845251A1 (en) * | 2005-09-12 | 2007-03-22 | The Ohio State University Research Foundation | Compositions for the therapy of bcl2-associated cancers and methods of preparation thereof |
| US7390792B2 (en) * | 2005-12-15 | 2008-06-24 | Board Of Regents, The University Of Texas System | MicroRNA1 therapies |
| JP5490413B2 (ja) * | 2006-01-05 | 2014-05-14 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | 膵内分泌腫瘍及び膵腺房腫瘍におけるマイクロｒｎａ発現異常 |
| JP5127821B2 (ja) * | 2006-04-24 | 2013-01-23 | ジ・オハイオ・ステイト・ユニバーシティ・リサーチ・ファウンデイション | ｍｉＲ１５５トランスジェニックマウスにおけるプレＢ細胞増殖及びリンパ芽球性白血病／高悪性度リンパ腫 |
| EP2076599A2 (en) * | 2006-09-19 | 2009-07-08 | Asuragen, Inc. | Mir-200 regulated genes and pathways as targets for therapeutic intervention |
| JP2010510964A (ja) * | 2006-09-19 | 2010-04-08 | アシュラジェン インコーポレイテッド | 治療的介入の標的としての、ｍｉＲ−１５、ｍｉＲ−２６、ｍｉＲ−３１、ｍｉＲ−１４５、ｍｉＲ−１４７、ｍｉＲ−１８８、ｍｉＲ−２１５、ｍｉＲ−２１６、ｍｉＲ−３３１、ｍｍｕ−ｍｉＲ−２９２−３ｐによって調節される遺伝子および経路 |
| CN101535505A (zh) * | 2006-09-19 | 2009-09-16 | 俄亥俄州立大学研究基金会 | 慢性淋巴细胞性白血病(CLL)中受miR-29和miR-181调控的TCL1的表达 |
| WO2008036765A2 (en) * | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | Micrornas differentially expressed in pancreatic diseases and uses thereof |
| EP2087135B8 (en) * | 2006-11-01 | 2013-07-24 | The Ohio State University Research Foundation | Microrna expression signature for predicting survival and metastases in hepatocellular carcinoma |
| US8293684B2 (en) * | 2006-11-29 | 2012-10-23 | Exiqon | Locked nucleic acid reagents for labelling nucleic acids |
| WO2008070082A2 (en) * | 2006-12-04 | 2008-06-12 | The Johns Hopkins University | Stem-progenitor cell specific micro-ribonucleic acids and uses thereof |
| DK2104737T3 (da) * | 2006-12-08 | 2013-05-27 | Asuragen Inc | Funktioner og formål for let-7 mikro-RNAer |
| WO2008073920A2 (en) * | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Mir-21 regulated genes and pathways as targets for therapeutic intervention |
| WO2008073915A2 (en) * | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | Micrornas differentially expressed in leukemia and uses thereof |
| EP2104734A2 (en) * | 2006-12-08 | 2009-09-30 | Asuragen, INC. | Mir-20 regulated genes and pathways as targets for therapeutic intervention |
| CA2671270A1 (en) * | 2006-12-29 | 2008-07-17 | Asuragen, Inc. | Mir-16 regulated genes and pathways as targets for therapeutic intervention |
| CN105256004A (zh) * | 2007-01-31 | 2016-01-20 | 俄亥俄州立大学研究基金会 | 用于急性髓细胞白血病(aml)的诊断、预后和治疗的基于微rna的方法和组合物 |
| CA2685840C (en) * | 2007-04-30 | 2016-12-13 | The Ohio State University Research Foundation | Methods for differentiating pancreatic cancer from normal pancreatic function and/or chronic pancreatitis |
| US20090005336A1 (en) * | 2007-05-08 | 2009-01-01 | Zhiguo Wang | Use of the microRNA miR-1 for the treatment, prevention, and diagnosis of cardiac conditions |
| US20090131354A1 (en) * | 2007-05-22 | 2009-05-21 | Bader Andreas G | miR-126 REGULATED GENES AND PATHWAYS AS TARGETS FOR THERAPEUTIC INTERVENTION |
| WO2008154098A2 (en) * | 2007-06-07 | 2008-12-18 | Wisconsin Alumni Research Foundation | Reagents and methods for mirna expression analysis and identification of cancer biomarkers |
| EP2719773A3 (en) * | 2007-06-15 | 2014-07-30 | The Ohio State University Research Foundation | miRNA as marker for acute lamphomic leucemia |
| JP2010535473A (ja) * | 2007-08-03 | 2010-11-25 | ズィ、オハイオウ、ステイト、ユーニヴァーサティ、リサーチ、ファウンデイシャン | ｎｃＲＮＡをコードする超保存領域 |
| US20090061424A1 (en) * | 2007-08-30 | 2009-03-05 | Sigma-Aldrich Company | Universal ligation array for analyzing gene expression or genomic variations |
| US20090123933A1 (en) * | 2007-11-12 | 2009-05-14 | Wake Forest University Health Sciences | Microrna biomarkers in lupus |
| US8071562B2 (en) * | 2007-12-01 | 2011-12-06 | Mirna Therapeutics, Inc. | MiR-124 regulated genes and pathways as targets for therapeutic intervention |
| WO2009086156A2 (en) * | 2007-12-21 | 2009-07-09 | Asuragen, Inc. | Mir-10 regulated genes and pathways as targets for therapeutic intervention |
-
2009
- 2009-02-27 AU AU2009219193A patent/AU2009219193A1/en not_active Abandoned
- 2009-02-27 CA CA2717026A patent/CA2717026A1/en not_active Abandoned
- 2009-02-27 US US12/919,904 patent/US20110052502A1/en not_active Abandoned
- 2009-02-27 CN CN2009801145645A patent/CN102015027A/zh active Pending
- 2009-02-27 EP EP20090715356 patent/EP2254668A4/en not_active Ceased
- 2009-02-27 JP JP2010548901A patent/JP2011517932A/ja active Pending
- 2009-02-27 WO PCT/US2009/035463 patent/WO2009108856A2/en not_active Ceased
-
2012
- 2012-06-28 US US13/536,837 patent/US20120283310A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011517932A5 (https=) | ||
| US20200232045A1 (en) | Methods of identifying individuals at increased risk of lung cancer | |
| Yu et al. | IFITM1 promotes the metastasis of human colorectal cancer via CAV-1 | |
| Zhang et al. | Genome-wide DNA methylation profiling identifies ALDH1A3 promoter methylation as a prognostic predictor in G-CIMP− primary glioblastoma | |
| US20130337449A1 (en) | Marker for predicting gastric cancer prognosis and method for predicting gastric cancer prognosis using the same | |
| JP2011516032A5 (https=) | ||
| JP2012500389A5 (https=) | ||
| JP2013514074A5 (https=) | ||
| ES2772701T3 (es) | Uso de nucleosomas libres de células como biomarcadores en muestras de esputo | |
| Maldonado et al. | Integrated transcriptomic and epigenomic analysis of ovarian cancer reveals epigenetically silenced GULP1 | |
| Chen et al. | Reduced expression of serum miR-204 predicts poor prognosis of gastric cancer | |
| CA3031580A1 (en) | Combination test for colorectal cancer | |
| EP4182480A1 (en) | Prognostic biomarkers for cancer | |
| CN108728545A (zh) | 结直肠癌长链非编码rna-hotair分子标志物及其应用 | |
| RU2007141930A (ru) | Способ in vitro идентификации соединений для лечения рака | |
| EP2680003A1 (en) | Serum biomarker for diagnosing colorectal cancer | |
| WO2012170614A2 (en) | Dna methylation markers in non-small cell lung cancer and methods of using the same | |
| CN115873955B (zh) | 一种用于评估顺铂治疗肺腺癌敏感性的试剂盒 | |
| WO2016181979A1 (ja) | Ｓｙｔ７・ｍｆｓｄ４・ｅｔｎｋ２発現量による胃癌肝転移の検査方法、検査キット、分子標的治療薬スクリーニング方法、医薬組成物 | |
| US20150011411A1 (en) | Biomarkers of cancer | |
| US9874565B2 (en) | Oncogene associated with human cancers and methods of use thereof | |
| Mo et al. | LRPPRC promotes the progression of colorectal cancer via HIF-1ꭤ/VEGF-meditated angiogenesis | |
| US20150253340A1 (en) | Method of cancer diagnosis, progression and response to therapy using a primary xenograft mouse model for cancer serum biomarker discovery | |
| US20180305759A1 (en) | Use of cell-free nucleosomes as biomarkers in fecal samples | |
| US20200232041A1 (en) | Methods For Diagnosis And Treatment Of Patients Having Solid Tumors |